ProShare Advisors’s Passage Bio PASG Stock Holding History

ProShare Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-628	Closed	-$38K	–	2026
2022 Q1	$38K	Sell	628 -158	-20%	-$13K	﹤0.01%	2132
2021 Q4	$100K	Sell	786 -29	-4%	-$4.74K	﹤0.01%	2206
2021 Q3	$162K	Sell	815 -151	-16%	-$36K	﹤0.01%	1832
2021 Q2	$256K	Buy	966 +216	+29%	+$66.8K	﹤0.01%	1991
2021 Q1	$262K	Buy	750 +123	+20%	+$52.5K	﹤0.01%	1876
2020 Q4	$321K	Buy	+627	New	+$251K	﹤0.01%	1565

Other funds holding PASG

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's PASG Position: Q2 2022 in Review

ProShare Advisors sold out of Passage Bio (PASG) in Q2 2022, closing a stake of 628 shares — an estimated $38K sold.

ProShare Advisors first reported a position in PASG in Q4 2020 and held it in 6 quarters. The position peaked at $321K in Q4 2020. 85 funds tracked by Wall St. Rank hold PASG as of Q2 2022.

ProShare Advisors reported no remaining Passage Bio position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 628 Passage Bio shares in Q2 2022, an estimated $38K.
ProShare Advisors first reported a position in Passage Bio in Q4 2020 and held it in 6 quarters.
ProShare Advisors's Passage Bio position peaked at $321K in Q4 2020.
85 funds tracked by Wall St. Rank held Passage Bio as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.